Patent: 9,499,619

Summary for Patent: 9,499,619

Title:	Polyclonal bispecific antibody compositions and method of use
Abstract:	The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.
Inventor(s):	Lum; Lawrence G. (Harrison Township, MI), Huang; Manley (Palo Alto, CA)
Assignee:	TRANSTARGET, INC. (Burlingame, CA) WAYNE STATE UNIVERSITY (Detroit, MI)
Application Number:	14/637,194
Patent Claims:	see list of patent claims

US Patent 9,499,619 (Composition of Polyclonal Armed Bispecifics): What It Claims and Where It Stands in the U.S. Patent Landscape

Executive summary

US 9,499,619 claims a cellular immunotherapy composition built from (i) cytotoxic immune cells armed with a heterogeneous population of polyclonal bispecific binding molecules and (ii) a specific architecture and antibody source/processing for the bispecifics. The claims are broad on cell types and pathogen scope, but they narrow through specific structural features (first moiety targets a cytotoxic-cell surface antigen; second moiety is a polyclonal mix against multiple epitopes on one or more pathogen antigens expressed on infected cells) and through known antibody/Ig sources and depletion constraints (e.g., IVIG, CYTOGAM; Ig depleted of anti-HLA; autologous/allogeneic origin). From an IP risk and diligence perspective, the key business question is whether competitors can avoid infringement by using (a) non-polyclonal second moieties, (b) non-fused architectures, (c) different targeting logic for the “first moiety,” (d) different Ig sources/processing (including HLA depletion), or (e) different arming dosing ranges and cell preparation approaches.

---

What patents protect compositions of polyclonal bispecific binding molecules for armed cytotoxic immune cells?

US 9,499,619 is a composition-claiming patent, focused on “armed” cells plus a bispecific molecular population. Its protection is driven by claim 1 and the dependent claim narrowing set out in your claim text. The most enforceable hook is that the bispecifics are polyclonal on the pathogen side and are fused to a cytotoxic-cell-binding moiety, then heterogeneously populated in the armed cell product.

Core claim 1 elements that define the patent’s protective perimeter

Claim 1 requires all of the following:

1. A heterogeneous population of polyclonal bispecific binding molecules.
2. Each bispecific has:
   • a first antigen binding moiety that binds an antigen on the surface of a cytotoxic immune cell; the first moieties may be same or different.
   • a second antigen binding moiety that is a heterogeneous polyclonal population binding to multiple different epitopes on one or more pathogenic antigens on infected cells.
3. The first moiety is fused to the second moiety to form the bispecific binding molecule.
4. The composition is used such that cytotoxic cells are the relevant target cell surface and the pathogen antigens are expressed/presented on infected cells.

Claim 2-4: cell-type and antibody-form tightening

• Claim 2 narrows cell types to activated T-cells, NK cells, dendritic cells, macrophages.
• Claim 3 restricts both moieties to antibodies or antibody fragments.
• Claim 4 distinguishes the moieties’ clonality:
  • first moiety: monoclonal (or fragment)
  • second moiety: polyclonal (or fragments)

Practical implication: A product with monoclonal/multispecific pathogen binding instead of polyclonal epitope coverage is an immediate design-around lever.

Claims 5-9: second-molecule heterogeneity, epitope multiplicity, Ig source, and HLA depletion

• Claim 5: at least two distinct antibodies as second moieties, each with different epitope specificity.
• Claim 6: second-molecule polyclonal population derived from Ig-enriched serum fraction.
• Claim 7: Ig serum fraction is depleted of antibodies recognizing human leukocyte antigen (HLA) molecules.
• Claims 8-9: polyclonal antibody derived from autologous or allogeneic donor(s).

Practical implication: If a competitor’s pathogen-side polyclonal component uses an Ig source that is not “Ig-enriched serum fraction” or does not incorporate anti-HLA depletion, the patent’s dependent claims may not be implicated, while claim 1 still poses risk if claim 1’s elements are met.

Claims 12-14: explicit first-moiety targets (CD markers) and anti-CD3 example

• Claim 12: first moiety binds one of CD2, CD3, CD4, CD5, CD8, CD11b, CD14, CD16a, CD28, CD45, CD56.
• Claim 13: first moiety is functional equivalent categories of binding to such molecules.
• Claim 14: explicit example: anti-CD3 antibody including OKT3 (or functional equivalent).

Practical implication: A competitor selecting a different immune-cell surface target outside this list (and not functionally equivalent) could reduce dependence on these narrower claims, but claim 1’s broader “surface antigen on cytotoxic immune cell” language still creates risk if the first moiety matches functionally.

Claims 15-19: arming and dose ranges for the bispecific population

• Claim 15: cytotoxic immune cell is armed with the polyclonal bispecific population.
• Claims 17-19: arming dose specified in ng per 10^6 immune cells:
  • 0.001 to 50 ng per 10^6 cells
  • 0.01 to 5 ng per 10^6 cells
  • 0.1 to 1.0 ng per 10^6 cells

Practical implication: Dose windows can matter for infringement if the competitor’s operational dosing is outside the claimed ranges and if the claim construction ties “arming dose” to those ranges as required features.

Claims 20-28: pathogen breadth with explicit examples and an IVIG/CYTOGAM path

• Claim 20-23: pathogen can be infectious agents, viruses listed (CMV, HAV, HBV, HCV, EBV, BKV, HSV, HIV, HPV).
• Claim 24: explicit virus: CMV.
• Claims 25-26: second moiety derived from IVIG preparation, specifically CYTOGAM.
• Claims 27-28: fungi including Pneumocystis carinii or Aspergillus.

Practical implication: This section is the strongest specificity for infringement targeting because it pins the pathogen-side polyclonal input to well-known immunoglobulin products and named indications.

---

What are the strongest, most infringement-relevant claim elements in US 9,499,619?

Most infringement-relevant features are those that are both (a) structurally defining and (b) harder to re-engineer without changing the product concept:

1. Fused bispecific architecture where the first-cell binder and second-pathogen binder are linked into a single bispecific molecule.
2. Polyclonal heterogeneity on the pathogen side:
   • multiple epitopes
   • multiple distinct antibodies in the second moiety population
3. Polyclonal origin and processing constraints:
   • derived from Ig-enriched serum fraction
   • depleted of anti-HLA antibodies
4. Arming of cytotoxic immune cells with the polyclonal bispecific population.
5. Defined first moiety binding targets, especially anti-CD3/OKT3 pathways if implemented.

Less infringement-relevant features are those that are either broad (pathogen categories) or likely easily varied (cell source) unless the competitor also mirrors the specific Ig product or HLA depletion constraints.

---

When does US 9,499,619 lose exclusivity in the U.S.?

You provided the claims but not the patent’s filing date, priority date, grant date, maintenance status, or terminal disclaimer facts. Those inputs determine the maintenance-based expiration under 35 USC § 154 and any PTA/terminal disclaimer effects. With those missing, an exclusivity timeline would not be complete and accurate.

---

How many patents cover polyclonal bispecific armed immune cell compositions in the U.S.?

A complete landscape requires bibliographic capture of US 9,499,619’s family, plus citation-based and assignee-based clustering across related claims. You did not provide:

• the patent’s inventors/assignee
• the continuation or priority family
• the publication numbers (US applications / PCT / EP / WO)
• the relevant cited art and prosecution history

Without those elements, the number of covering patents cannot be determined reliably.

---

Which companies are challenging US 9,499,619 with Paragraph IV or equivalent litigation?

You provided claims text only, not litigation dockets, FDA Orange Book listings, or Paragraph IV filings. US 9,499,619 is a biologics/cell-therapy type composition patent, where challenges often arise through:

• product-specific litigation (non-Paragraph IV for many biologic frameworks),
• trade-secret or method-adaptation disputes,
• or patent use codes tied to an FDA reference product.

Without the patent’s Orange Book/biologics listing linkage and case captions, a litigation mapping cannot be produced completely.

---

What is the Orange Book status of US 9,499,619?

Orange Book status depends on whether the asserted patent is listed for an approved drug product with an NDC and relevant listed patent numbers. That linkage is not provided.

---

How strong is the patent estate for polylconal-bispecific armed cytotoxic cells?

Strength here is an IP-claim quality question, not a “likely outcome” question.

Technical strength: claim specificity around the second moiety source and HLA depletion

The dependent claims tether the pathogen-side polyclonal input to:

• Ig-enriched serum fraction
• anti-HLA antibody depletion
• explicit IVIG preparations (including CYTOGAM)

If an accused product uses IVIG-derived polyclonal components with anti-HLA depletion, the dependent claims become powerful. If it does not, those narrower hooks weaken quickly.

Legal strength: claim 1’s structural definition is conceptually coherent

Claim 1’s “fused bispecific” plus “polyclonal epitope coverage” plus “armed cytotoxic immune cell” is a clean combination that can support a non-trivial infringement theory if a competitor ships an armed-cell product made using the same bispecific design.

Weakness vector: “polyclonal” and “heterogeneous population” are design intent terms that can be engineered around

Competitors can attempt to avoid:

• polyclonal epitope coverage by using defined mixtures of monoclonal antibodies (still “multiple antibodies” but not truly polyclonal from serum fraction as claimed),
• by swapping non-Serum Ig enrichment sources or omitting HLA depletion steps,
• by altering architecture so that first and second binders are not fused into a single bispecific molecular species,
• by using non-armed or different activation/engagement mechanisms.

Weakness vector: pathogen breadth is large, but examples exist

Claim 1 is broad on pathogens being “infectious agent” and includes virus examples and fungus examples. Broad scope can help enforcement if the product falls within the structural elements. It can also be attacked if prior art shows armed immune-cell therapies with bispecifics or Ig-derived binders in general, depending on the patent’s actual priority and disclosure basis.

---

What formulations are protected by US 9,499,619?

US 9,499,619 protects not just the molecular bispecific but the composition defined as:

• a heterogeneous population of fused bispecific molecules, and
• a cellular composition where cytotoxic immune cells are armed with that population.

Dosage form and administration implications from claim text

The claim does not specify a dosage form like injectable solution, lyophilizate, or implant. It focuses on:

• per-cell arming dose ranges (ng per 10^6 cells),
• cell types for ex vivo preparation.

Thus protection is oriented to manufactured cell product formulation.

---

What method-of-use patents exist for this type of therapy, and how do they compare?

Your provided text includes composition claims only. Method-of-use coverage would typically sit in parallel patents or continuation claims with:

• “treating” steps,
• infectious disease indications (CMV, HIV, HCV, EBV, etc.),
• immune activation/regimen details.

Because you have not provided bibliographic family information, a comparison to method-of-use patents cannot be made.

---

What patent litigation affects products using armed cytotoxic cells with bispecific or Ig-derived binding?

No litigation identifiers are provided. Without:

• case numbers,
• venue,
• asserted patent list,
• settlement terms,
• injunction posture, a litigation impact analysis cannot be produced.

---

What generic entry risks exist for US 9,499,619?

For biologics and engineered cell therapies, “generic entry” usually translates to:

• biosimilar-style pathways when applicable,
• or to “follow-on” cell therapies under different regulatory frameworks,
• plus patent infringement and licensing exposure.

You have not provided regulatory linkage (FDA approval status, reference product, BLA type), so “entry risk” cannot be mapped to a launch timeline.

---

How does US 9,499,619 compare with adjacent bispecific and armed-cell patent strategies?

Based strictly on claim text, the distinguishing features are:

Distinction 1: polyclonal epitope coverage on the pathogen side

Many bispecific strategies use:

• fully defined monoclonals (single clone or limited mixture),
• or engineered single-chain variable fragments from defined specificities.

Here, the second moiety is a polyclonal heterogeneous population binding multiple epitopes on infected-cell antigens.

Distinction 2: Ig-source specificity and anti-HLA depletion

The claims explicitly require an Ig serum fraction depleted of HLA-recognizing antibodies, and also cite IVIG preparation (CYTOGAM).

Distinction 3: fused bispecific molecular format

A competitor using non-fused mixtures (separate first and second binders applied independently) may attempt to design around if the “fused to form the bispecific” requirement is not met.

---

Where are the main design-around levers?

If the goal is to reduce infringement risk against claim 1 and its dependents, the engineering levers in the claims are:

1. Avoid fused bispecific molecules where first and second moieties are physically fused into one molecule.
2. Replace the pathogen-side polyclonal second moiety with a composition that is not a “heterogeneous polyclonal population … against multiple different epitopes” produced under the claimed sourcing concepts.
3. Remove the anti-HLA depletion step if operating outside claim 7 dependent scope.
4. Use different Ig inputs than “Ig enriched serum fraction” or specified IVIG preparations such as CYTOGAM.
5. Change “arming” approach so cells are not “armed with the population” as claimed, or dose falls outside the dependent arming ranges (claims 17-19).
6. Change first moiety target outside the enumerated CD list and avoid functional equivalence to the specified molecules if those dependent claims are asserted.

---

Key Takeaways

• US 9,499,619 claims a cell-armed therapy using fused bispecific binding molecules where the first moiety targets a cytotoxic immune cell surface antigen and the second moiety is a polyclonal pathogen-binding mixture against multiple epitopes on infected cells.
• The patent’s enforceability is most sensitive to manufacturing facts: bispecific fusion vs mixed components, polyclonal vs defined monoclonal mixtures, Ig source and anti-HLA depletion, and arming dose and process.
• Dependent claims add high-value specificity through Ig-enriched serum fraction, anti-HLA depletion, IVIG/CYTOGAM, and anti-CD3/OKT3 exemplars.
• A full competitive and litigation landscape (expiration, Orange Book listing, Paragraph IV/biosimilar challenges, and assignee map) cannot be computed from claims text alone.

---

FAQs

1. What does “polyclonal bispecific binding molecules” require for infringement analysis?
2. How does “fused to form the bispecific” affect design-around strategies like co-administration of separate binders?
3. Does anti-HLA depletion matter only for dependent claim 7 or for claim 1 as well?
4. If a competitor uses IVIG but not CYTOGAM, which claims are most exposed?
5. Which claim elements are most likely to be disputed in claim construction: “heterogeneous population,” “multiple epitopes,” or “infected cell presentation”?

---

References

(Only numbered references are allowed. No sources were provided in the prompt, and the patent’s publication/bibliographic identifiers and prosecution records were not supplied.)

Details for Patent 9,499,619

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kamada Ltd.	CYTOGAM	cytomegalovirus immune globulin intravenous (human)	Injection	103189	April 17, 1990		2035-03-03